Tarsus Pharmaceuticals (TARS) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Do institutionals and insiders believe in BPMC or TARS?

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer BPMC or TARS?

Blueprint Medicines received 499 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 67.90% of users gave Tarsus Pharmaceuticals an outperform vote while only 67.15% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 554 67.15%	Underperform Votes 271 32.85%
Tarsus Pharmaceuticals	Outperform Votes 55 67.90%	Underperform Votes 26 32.10%

Do analysts prefer BPMC or TARS?

Blueprint Medicines currently has a consensus price target of $129.71, indicating a potential upside of 1.41%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 51.17%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media prefer BPMC or TARS?

In the previous week, Blueprint Medicines had 63 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 76 mentions for Blueprint Medicines and 13 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.91 beat Blueprint Medicines' score of 0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	18 Very Positive mention(s)	14 Positive mention(s)	26 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, BPMC or TARS?

Blueprint Medicines has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Is BPMC or TARS more profitable?

Blueprint Medicines has a net margin of -13.19% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%

Which has stronger earnings and valuation, BPMC or TARS?

Blueprint Medicines has higher revenue and earnings than Tarsus Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	14.69	-$67.09M	-$2.47	-51.78
Tarsus Pharmaceuticals	$233.67M	7.93	-$135.89M	-$2.73	-16.15

Summary

Blueprint Medicines and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.